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Abstract
Background: Many adjuvant trials have been undertaken in an attempt to reduce the risk of recurrence among
patients who undergo surgical resection for locally advanced renal cancer. However, no clear benefit has been
identified to date. This systematic review was conducted to examine the exact role of adjuvant therapy in renal
cancer setting.
Methods: Randomized controlled trials were searched comparing adjuvant therapy (chemotherapy, vaccine,
immunotherapy, biochemotherapy) versus no active treatment after surgery among renal cell cancer patients.
Outcomes were overall survival (OS), disease-free survival (DFS), and severe toxicities. Risk ratios (RR), hazard ratios
(HR) and 95% confidence intervals were calculated using a fixed-effects meta-analysis. Heterogeneity was measured
by I
2. Different strategies of adjuvant treatment were evaluated separately.
Results: Ten studies (2,609 patients) were included. Adjuvant therapy provided no benefits in terms of OS (HR 1.07;
95%CI 0.89 to 1.28; P = 0.48 I
2 = 0%) or DFS (HR 1.03; 95%CI 0.87 to 1.21; P = 0.77 I
2 = 15%) when compared to no
treatment. No subgroup analysis (immunotherapy, vaccines, biochemotherapy and hormone therapy) had relevant
results. Toxicity evaluation depicted a significantly higher frequency of serious adverse events in the adjuvant
group.
Conclusions: This analysis provided no support for the hypothesis that the agents studied provide any clinical
benefit for renal cancer patients although they increase the risk of toxic effects. Randomized trials are underway to
test targeted therapies, which might open a new therapeutic frontier. Until these trials yield results, no adjuvant
therapy can be recommended for patients who undergo surgical resection for renal cell cancer.
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Background
Renal cancer is among the tenth most common cancers
and its incidence has increased constantly in recent dec-
ades [1]. Two thirds of patients have no evidence of dis-
tant metastasis at diagnosis, and radical surgery can be
curative. However, just a fraction of these patients are
effectively cured by surgery as recurrence occurs in a
high proportion of cases [2].
In the last 30 years, only a few drugs have shown
some activity against advanced renal cancer. Initially
immunomodulators, namely, interferon and interleukin-
2, were used to control metastatic disease and, in
unpredictable instances, could stabilize the disease for
years or even eliminate it completely [3,4].
The existence of rare but exceptional results with
immunomodulators in metastatic patients triggered
initiation of trials testing these drugs, combined or not
with antineoplastic agents in the adjuvant setting. Some
trials tested immunotherapy (interleukin or interferon)
or vaccines derived from tumor cells. Conventional anti-
neoplastic agents or hormonal therapy were also tested
[5,6]. Unfortunately, such therapies have not shown
clear evidence of survival improvement to date [7,8].
Targeted therapies are already being tested in the adju-
vant setting, however no mature survival data are cur-
rently available.
In this scenario, we carried out a systematic review
with meta-analysis of randomized trials to address the
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undergo surgical resection for renal cell cancer.
Methods
The present systematic review was originally completed
in the context of an evidence-based training, based on
the Centre of Evidences in Oncology (CEVON) work-
group, in the State University of Campinas (UNICAMP),
Brazil. All the evidences were selected and reviewed by
two members of CEVON and discussed with the group
and the coordinator (ADS). All work produced by
CEVON is editorially independent and does not have
any funding source.
Search strategy
Studies were searched and identified in electronic data-
bases (PubMed/MEDLINE, EMBASE, LILACS, Clinical-
Trials.gov and The Cochrane Library). Websites for
A S C O ,A U A ,E C C Oa n dE S M Om e e t i n g sw e r ea l s o
scrutinized. We used a sensitive search strategy with
words related to kidney (kidney OR renal), cancer
(tumor OR neoplasm OR carcinoma OR cancer), adju-
vant therapy (chemotherapy OR drug therapy OR
immunotherapy OR biotherapy OR hormone*), and ran-
domized trials (random* OR randomized trials) in all
fields. The search was restricted to trials published or
presented in English.
We hand-searched the reference lists of related
reviews for additional publications. All references of
relevant articles were scanned and all additional studies
of potential interest were retrieved for further analysis.
The search included literature published or presented
until June 2010.
Selection criteria
We sought to identify all published or presented rando-
mized controlled clinical trials comparing post-surgical
therapy versus no further active therapy (placebo or
observation) in patients who underwent surgery for
renal cell cancer. Eligible trials included patients with
renal cell cancer of any histological type, with no sign of
metastases and rendered disease free after radical sur-
gery. Trials enrolling patients with metastatic and non-
metastatic disease were included if separate information
on non-metastatic patients was provided. Trials invol-
ving radiation as adjuvant therapy were excluded.
The original published articles of all relevant citations
were retrieved for a more detailed analysis. No attempt
was made to restrict the search according to more spe-
cific methodological characteristics.
Two reviewers (AJOS and ADS) analyzed the list of
references and independently selected the studies. The
final selection of which studies to include was achieved
by consensus.
Data extraction
The name of the first author and the year of publication
of the article were used for identification purposes. Two
reviewers (AJOS and ADS) independently extracted the
data from the studies. A third reviewer (CSPL) was con-
sulted to solve disagreements.
The primary outcome analyzed was overall survival
(OS). Other endpoints of interest were disease-free sur-
vival (DFS), and the incidence of Common Toxicity Cri-
teria (CTC) scale grade 3/4 toxicities. When the
published article did not present needed data to deter-
mine OS or DFS, the authors were contacted to provide
the information. Toxicity data were retrieved, as avail-
able, in the publication.
The hazard ratios (HRs) of time-to-event data (OS and
DFS) were directly extracted from the original study or
were estimated indirectly using either the reported num-
ber of events and the corresponding P value for the log-
rank statistics, or by reading off survival curves, as sug-
gested by Parmar and colleagues [9]. The calculations
were carried out using the spreadsheet provided by
Tierney and colleagues [10]. The number of events and
number under risk were abstracted for toxicity
comparison.
Statistical analysis and synthesis
Details regarding the main methodological dimensions
empirically related to bias [11] were extracted, and the
methodological quality of each selected trial was
assessed by two reviewers (AJOS and ADS). Special
attention was given to the generation and concealment
of the sequence of randomization, blinding, whether an
intention-to-treat analysis was performed or not, use of
placebo, and source of funding. These data were applied
in a subgroup, and sensitivity analyses were performed
to test the stability of our conclusions.
All meta-analyses were performed using Review Man-
ager 5 (RevMan 5; The Nordic Cochrane Centre, The
Cochrane Collaboration, Copenhagen, Denmark) with a
fixed-effect model. Time-to-event outcomes were com-
pared using HR while an odds ratio (OR) was used for
toxicity evaluation. The effect of the treatment was
expressed as a ratio of active therapy arm over the pla-
cebo/observation arm. Thus, in OS and DFS evaluations,
an HR value less than 1 favored active therapy, whereas an
HR greater than 1 favored observation. Respective 95%
confidence intervals (CI) were calculated for each estimate.
In the safety analyses, an OR less than 1 favored active
therapy while an OR greater than 1 favored observation.
The number needed to harm (NNH) for risks, derived
from the inverse of the absolute risk difference, was also
used to measure toxicity risk.
Statistical heterogeneity of the results of the trials was
assessed by the chi-square (c
2)t e s t[ 1 2 ] ,a n dw a s
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2 index, as described by Higgins and
colleagues [13]. When a considerable heterogeneity was
detected (I
2 >40%), a possible explanation for it was pur-
sued. When a reasonable cause was found, then a sepa-
rate analysis was performed. If the cause was not
apparent and heterogeneity was caused by divergent
data in terms of direction of results (i.e., data favoring
one or other treatment), we chose not to pool the data.
Publication bias was evaluated by Egger’s test [11].
All different therapies - hormonal, biochemotherapy,
chemotherapy, vaccine, and immunotherapy - were ana-
lyzed separately to access their impact in survival and
safety.
Results
Literature Search
The systematic search is summarized in the QUOROM
flowchart (Figure 1). Twelve trials were identified that
were published or presented between 1987 and 2009
[5-8,14-21]. Two studies enrolled metastatic and non-
metastatic patients but no separate information of non-
metastatic was provided, which precluded their inclusion
in analyses [8,15]. The remaining ten trials comprised
2609 patients. Six trials, (1,997 patients) had mature OS
data [7,14,16,18-20] while DFS was reported in all
studies.
Eligible trials enrolled high-risk patients. Approxi-
mately 60% of patients had lymph node positive disease
while 86% had pT2 or more advanced disease. No
patient had previously received systemic therapy. None
of selected trials was a placebo-controlled, double-blind
trial. The Wood trial demanded a minimum clear cells
component (25%) in tumor burden [19]. The remaining
trials accepted all pathological subtypes. Considering the
selected studies, three were carried out in the United
States, six in Europe, and one in Japan. Methodological
details potentially related to bias are described in
Table 1.
Three studies tested vaccine therapy [16,17,19], three
interleukin/interferon therapy [7,18,20] without high
dose therapy, one biochemotherapy [14], one hormone
therapy [5], one thalidomide [21] and one chemotherapy
alone [6]. A detailed description of treatment arms for
all included studies is presented in Table 2.
Overall Survival
The impact of adjuvant treatment on OS was extracted
directly or estimated indirectly from published data
of six trials with mature data (1,997 patients) [7,14,
16,18-20]. No single study demonstrated a statistically
significant improvement in OS. Funnel plots of all com-
parisons did not identify a publication bias.
As the trials whose results were analyzed involved the
use a multitude of agents, some of them with limited
activity in advanced disease, the subgroups are shown
and described individually.
Vaccine therapy
Two trials identified (848 patients) provided OS data on
vaccine therapy [16,19]. Meta-analysis demonstrated
that adjuvant therapy was not capable of improving OS
(HR = 1.02; 95% CI 0.75 to 1.39; P = 0.89; Figure 2).
There was no heterogeneity between trials (I
2 = 0%).
Immunotherapy
Three trials (840 patients) with immunotherapy were
gathered and there was no sign of OS improvement (HR
= 1.18; 95% CI 0.90 to 1.56; P = 0.23; Figure 2) [7,18,20].
Again, no heterogeneity was found (I
2 = 0%).
Other Therapies
The systematic review found only one trial testing bio-
chemotherapy (5-fluorouracil associated with interferon
alfa/interleukin 2) [14]. There was no survival gain with
biochemotherapy (HR = 0.91; 95% CI 0.60 to 1.38; P =
0.66; Figure 2).
Figure 1 QUOROM flowchart of the systematic literature
review. Abbreviations: RCT: randomized controlled trial.
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mide, and another one hormone therapy (medroxipro-
gesterone) [5,6,21]. None presented OS data.
The meta-analysis of all studies demonstrated that the
agents studied did not improved OS (HR = 1.07; 95%CI
0.89 to 1.28; P = 0.46; Figure 2). There was no heteroge-
neity between trials (I
2 = 0%; P = 0.64).
Disease-free Survival
Information concerning DFS was available in all trials
(ten trials, 2,609 patients). Only one study demonstrated
a statistically significant result, favoring active therapy
[17].
O n em o r et i m e ,a st h et r i a l su s e dm a n yd i f f e r e n t
agents, some of them with no activity in advanced dis-
ease, the subgroups are shown and described
individually.
Vaccine Therapy
All three trials identified testing vaccines presented DFS
data (1,227 patients) [16,17,19]. The meta-analysis could
not identify a DFS gain (HR = 0.86; 95% CI 0.71 to 1.04;
P = 0.13; I
2 = 51%) (data not shown). Nevertheless an
elevated heterogeneity was found that demanded a more
detailed evaluation of this comparison.
Examining carefully the characteristics of each trial,
the study conducted by Jocham et al [17] seemed to be
the source of heterogeneity. Jocham et al applied
autologous vaccine in radically resected renal cancer
patients and was the unique trial identified with positive
impact in survival, more specifically, DFS. However, this
study had methodological restrictions. A large portion
of patients (41%) were not properly followed due to his-
tological incompatibilities, lost of follow-up, failure in
vaccine production, and staging flaws. Taking all these
into account, Jocham et al results must be viewed with
great caution. Excluding this trial from analysis (848
patients left) meta-analysis did not identify a DFS gain
while heterogeneity was eliminated (HR = 0.95; 95% CI
0.76 to 1.19; P = 0.68; I
2 = 0%; Figure 3).
Immunotherapy
All three trials (840 patients) with immunotherapy pro-
vided DFS data [7,18,20]. The meta-analysis was per-
formed with acceptable heterogeneity although no gain
could be observed (HR = 1.13; 95% CI 0.80 to 1.60; P =
0.48; I
2 = 40%; Figure 3).
Other Therapies
The situation of thalidomide, chemotherapy, hormone
therapy, and biotherapy was identical: the systematic
review identified just one trial testing each of these
therapies and no study demonstrated a survival benefit
of adjuvant treatment.
Naito [6] tested adjuvant UFT (HR = 0.85; 95% CI
0.26 to 2.82; P = 0.80); Pizzocaro [5] tested medroxipro-
gesterone (HR = 0.95; 95% CI 0.45 to 2.00; P = 0.90);
Figure 2 Overall survival meta-analysis of adjuvant therapies versus no therapy.
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0.93 to 5.88; P = 0.07), and Aitchison [14] applied 5-
fluorouracil and interferon alfa/interleukin 2 (HR = 0.87;
95% CI 0.64 to 1.19; P = 0.40).
The meta-analysis of all studies demonstrated that all
agents studied did not improved DFS (HR = 1.03; 95%
CI 0.87 to 1.21; P = 0.77) (Figure 3). There was no sig-
nificant heterogeneity between trials (I2 = 15%; P =
0.31).
Toxicity
Eight trials presented toxicity data (1,910 patients)
[5-7,16,17,19,20]. Adverse event descriptions were scarce
and no single toxicity was described across all trials.
Vaccine and immunotherapy caused mild but frequent
skin induration, injection site pain, and flu-like symp-
toms. Just one trial, which tested vaccine therapy,
described grade 3/4 neutropenia (RR = 62.33; P = 0.004)
and anemia (RR = 3.06; P = 0.49) [7]. No trial described
neutropenic fever, thrombocytopenia, or grade 5 events.
Despite the absence of details, most severe toxicities
were presented in each trial and therefore worst toxicity
meta-analysis was feasible. Table 3 depicts the number
of grade 3/4 events among the patients at risk (safety
population).
Discussion
This systematic review sought to identify all types of
drug interventions used as post-surgical therapy for
resected renal cell cancer. The evidence indicates that
the adjuvant approaches studied are not capable of
improving survival of non-metastatic renal cancer
patients while exposing patients to unnecessary toxicity.
We included a broad spectrum of interventions to be
evaluated in this meta-analysis - immunotherapy, anti-
angiogenic, hormonal and cytotoxic drugs combined or
Figure 3 Disease-free survival meta-analysis of adjuvant therapy versus no therapy
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tive in what could be interpreted as an absence of activ-
ity for each one of these approaches in the adjuvant
setting.
Among the included trials, one deserves specific atten-
tion. Jocham et al [17] tested an autologous vaccine and
was the only trial to present a positive DFS result. How-
ever, these results might have been compromised due to
worrisome methodological issues discussed here and
elsewhere [22]. All this justified the exclusion of the Joc-
ham trial from DFS analysis.
The paucity of adverse event descriptions hampered
toxicity meta-analyses and many important events such
as febrile neutropenia, nausea, and hypotension could
not be evaluated. Even with incomplete reports, a worst
toxicity analysis clearly revealed the low tolerability of
these therapies.
The present study has the typical limitations and
strengths of an aggregated data meta-analysis. We found
no indication of such bias using statistical methods
designed to detect it. An analysis of individual patient
data would be more powerful to address this issue.
However it is hardly believable that an individual patient
data meta-analysis could be justified after the results of
this meta-analysis.
Recently accumulated data in the metastatic setting
indicates targeted therapies as the logical option to be
tested in adjuvant therapy. These drugs - sorafenib,
sunitinib - are already being tested in adjuvant rando-
mized trials (S-TRAC: sunitinib treatment of renal adju-
vant cancer; SORCE: sorafenib in treating patients at
risk of relapse after undergoing surgery to remove kid-
ney cancer and ASSURE: adjuvant sorafenib or sunitinib
for unfavourable renal carcinoma). Trial results will be
available between 2012 and 2016 [23].
Conclusions
This systematic review strengthens the evidence that no
studied systemic therapy provides improvement in survi-
val for patients who undergo surgical resection of renal
cell cancer. Results of targeted therapies in the adjuvant
context must be closely observed as they might repre-
sent an important shift in the prognosis of resected
renal cancer patients.
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